XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheet Account Detail (Tables)
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Cash and Cash Equivalents and Marketable Securities
The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”:
Historical or Amortized CostFair
Value		Cash and Cash
Equivalents		Marketable
 Securities
March 31, 2022
Money market funds$56,326 $56,326 $56,326 $— 
Equity securities(1)
3,508 4,655 — 4,655 
Mutual funds5,400 5,880 — 5,880 
Bank deposits22,353 22,353 22,353 — 
Total cash and cash equivalents and marketable securities$87,587 $89,214 $78,679 $10,535 
December 31, 2021
Equity securities(1)
$3,512 $5,718 $— $5,718 
Money market funds66,322 66,322 66,322 — 
Bank deposits22,217 22,217 22,217 — 
Mutual funds5,218 6,390 — 6,390 
Total cash and cash equivalents and marketable securities$97,269 $100,647 $88,539 $12,108 
(1)Our aggregate equity holdings consist of 4.7 million common shares of CASI Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $3.8 million as of March 31, 2022. We completed the sale of 0.4 million shares of common stock and recognized a $0.3 million gain within “other expense, net” within the accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2022. Additionally, we hold 0.7 million common shares of Unicycive Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $0.9 million as of March 31, 2022. We completed the sale of 0.2 million shares of common stock and recognized a $0.2 million gain within “other expense, net” within the accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2022.
Schedule of Accounts Payable and Other Accrued Liabilities “Accounts payable and other accrued liabilities” consists of the following:
March 31, 2022December 31, 2021
Trade accounts payable and other $25,305 $33,408 
Lease liability - current portion1,001 1,282 
Commercial Product Portfolio accruals (Note 7)6,269 6,568 
Accounts payable and other accrued liabilities $32,575 $41,258 
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of gross-to-net (“GTN”) estimates related to the Commercial Product Portfolio accruals were as follows:
Commercial/Medicaid Rebates and Government ChargebacksDistribution, Data, Inventory and
GPO Administrative Fees		Product Return AllowancesTotal
Balance as of December 31, 2020$2,601 $942 $4,299 $7,842 
(Less): Payments and credits against GTN accruals (1,159)— (115)(1,274)
Balance as of December 31, 2021$1,442 $942 $4,184 6,568 
(Less): Payments and credits against GTN accruals (35)— (264)(299)
Balance as of March 31, 2022$1,407 $942 $3,920 $6,269